NEW YORK (GenomeWeb) – PharmaFluidics said today it has closed a €7.3 million ($8.8 million) funding round.
The Ghent, Belgium-based firm said it will use the funds to further develop its microchip chromatography products and increase international sales.
PharmaFluidics' main product is its µPAC microchip chromatography columns, which it says offer improved sensitivity and separation performance compared to conventional chromatography. The company markets the technology for use in separating complex biological samples like biopsies and proteome digests. It began shipping columns in September 2017.
Several new investors participated in the round including the holding company FPIM-SFPI and the family offices Heran and RMM. Existing investors PMV, Qbic, Theodorus, Innovation Fund, and Volksvermogen also participated in the round.